Abbott Laboratories has decided not to exercise its license-back option for Speedel’s SPP200 which has recently completed a successful phase II trial in patients undergoing chronic haemodialysis.
Abbott Laboratories has decided not to exercise its license-back option for Speedel’s SPP200 which has recently completed a successful phase II trial in patients undergoing chronic haemodialysis.
